v3.23.1
Segment Information
 3 Months Ended
Mar. 31, 2023
Segment Reporting [Abstract]  
Segment Information Segment InformationAbbVie operates as a single global business segment dedicated to the research and development, manufacturing, commercialization and sale of innovative medicines and therapies. This operating structure enables the Chief Executive Officer, as chief operating decision maker (CODM), to allocate resources and assess business performance on a global basis in order to achieve established long-term strategic goals. Consistent with this structure, a global research and development and supply chain organization is responsible for the discovery, manufacturing and supply of products. Commercial efforts that coordinate the marketing, sales and distribution of these products are organized by geographic region or therapeutic area. All of these activities are supported by a global corporate administrative staff. The determination of a single business segment is consistent with the consolidated financial information regularly reviewed by the CODM for purposes of assessing performance, allocating resources and planning and forecasting future periods.The following table details AbbVie’s worldwide net revenues:
Three months ended
March 31,
(in millions)
20232022
Immunology
HumiraUnited States$2,948 $3,993 
International593 743 
Total$3,541 $4,736 
SkyriziUnited States$1,139 $781 
International221 159 
Total$1,360 $940 
RinvoqUnited States$449 $311 
International237 154 
Total$686 $465 
Hematologic Oncology
ImbruvicaUnited States$638 $874 
Collaboration revenues240 299 
Total$878 $1,173 
VenclextaUnited States$265 $228 
International273 245 
Total$538 $473 
Aesthetics
Botox CosmeticUnited States$409 $413 
International250 228 
Total$659 $641 
Juvederm CollectionUnited States$122 $148 
International233 262 
Total$355 $410 
Other AestheticsUnited States$246 $285 
International40 38 
Total$286 $323 
Neuroscience
Botox TherapeuticUnited States$587 $500 
International132 114 
Total$719 $614 
Vraylar
United States$560 $427 
International1 — 
Total$561 $427 
DuodopaUnited States$25 $24 
International93 97 
Total$118 $121 
UbrelvyUnited States$150 $138 
International2 — 
Total$152 $138 
QuliptaUnited States$66 $11 
Three months ended
March 31,
(in millions)
20232022
Other NeuroscienceUnited States$75 $173 
International4 4 
Total$79 $177 
Eye Care
OzurdexUnited States$39 $33 
International76 74 
Total115 107 
Lumigan/GanfortUnited States$63 $67 
International67 73 
Total$130 $140 
Alphagan/CombiganUnited States$28 $70 
International43 37 
Total$71 $107 
RestasisUnited States$79 $235 
International13 11 
Total$92 $246 
Other Eye CareUnited States$110 $91 
International90 80 
Total$200 $171 
Other Key Products
MavyretUnited States$171 $169 
International193 211 
Total$364 $380 
CreonUnited States$305 $287 
Linzess/ConstellaUnited States$251 $233 
International8 7 
Total$259 $240 
All other$691 $1,211 
Total net revenues$12,225 $13,538